Monday, March 27, 2017 6:05:01 AM
Commenting on the publication, John Dawson, Chief Executive Officer of Oxford BioMedica, said: "The data published demonstrates Oxford BioMedica's innovative capabilities and our commitment to invest in our technology to maintain our leading position in vector manufacture for gene therapy products. As demand for vectors grows with the introduction of gene and cell therapy products, we are confident there will be significant demand from third parties to licence the rights to utilise our TRiP technology."
-Ends-
http://uk.advfn.com/stock-market/london/oxford-biomedica-OXB/share-news/Oxford-Biomedica-PLC-Publication-in-the-Journal-Na/74187902
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM